Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788822 | 1.00 | NOS3 (0.43) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL2551316 | 0.82 | TDP1 (0.51) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL2475257 | 0.81 | ALDH1A1 (0.46) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL535504 | 0.81 | MAPT (0.50) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL29662541 | 0.81 | MAPT (0.50) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL28758700 | 0.80 | ALDH1A1 (0.55) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL2551785 | 0.80 | NOS3 (0.41) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL2478612 | 0.79 | NOS3 (0.50) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL1192691 | 0.79 | ALDH1A1 (0.49) | NOS3NOS1NOS2ALDH1A1MAPT | |
| SCHEMBL29414896 | 0.79 | ALDH1A1 (0.49) | NOS3NOS1NOS2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114907339-B | 4- (4-aminophenoxy) pyridin-2-amine derivatives and use thereof | 成都奥睿药业有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-114907339-A | 4- (4-aminophenoxy) pyridin-2-amine derivatives and uses thereof | 成都奥睿药业有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-2556068-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2370429-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| CN-102333770-B | P38 MAP kinase inhibitors | RESPIVERT LTD | 2015-01-28 | — | — | CN | disclosed |
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| CN-102333770-A | P38 map kinase inhibitors | RESPIVERT LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| EP-2370429-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067130-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | NOS3 395/4885NOS1 391/4885NOS2 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.